Jim Cramer on Johnson & Johnson: “If It Gets Blasted, Try to Get Some”

Johnson & Johnson (NYSE:JNJ) is among the stocks on Jim Cramer’s game plan as he shared his take on the market post Iran-U.S. ceasefire talks. Cramer noted that it has become his favorite drug stock instead of Eli Lilly, as he said:

Now, my favorite drug stock reports next week, too, and that’s not Lilly anymore. It’s Johnson & Johnson. We own this one for the Charitable Trust, and I think we’re going to hear that it has the most blockbusters and the best pipeline in the industry. This is a company transformed, shedding slower, growing divisions, focusing on research that can produce lifesaving drugs. I eagerly await this one. Now, word to the wise, it’s really important. JNJ has a habit of getting hammered on the news release when it comes out in the morning, okay, and then rallying, once the conference call starts. If it gets blasted, try to get some.

Johnson & Johnson (NYSE:JNJ) develops and sells healthcare products, including pharmaceuticals and medical technologies, with treatments in immunology, oncology, neuroscience, cardiovascular care, and infectious diseases.

While we acknowledge the risk and potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than JNJ and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.